Key result
Brain natriuretic peptide concentrations were higher in patients with confirmed heart failure than those without heart disease.
Why the study?
Does BNP measurement combined with echocardiography improve diagnostic accuracy and cost-effectiveness in patients with new symptoms of mild heart failure?
Observational (n=252)
Does BNP measurement combined with echocardiography improve diagnostic accuracy and cost-effectiveness in patients with new symptoms of mild heart failure?
A BNP cutoff of 50 ng/L is a cost-effective screening tool for early diagnosis of mild heart failure, significantly reducing the need for echocardiograms.
Answers are grounded in this paper and cite their sources.
May support BNP for early mild heart failure evaluation; leaves open whether combined echocardiography improves accuracy or cost-effectiveness.
BACKGROUND: The early identification of patients at risk for the development of clinical heart failure (HF) is a new challenge in an effort to improve outcomes. METHODS: We prospectively evaluated whether the combination of brain natriuretic peptide (BNP) measurements (Triage BNP test, Biosite Diagnostics) and echocardiography would effectively stratify patients with new symptoms in a cost-effective HF program aimed at early diagnosis of mild HF. A total of 252 patients were referred by 100 general practitioners. RESULTS: Among the study population, the median BNP value was 78 ng/L (range, 5-1491 ng/L). BNP concentrations were lower among patients without heart disease [median 15 ng/L (range, 5-167 ng/L); n = 96] than among patients with confirmed HF [median, 165 ng/L (22-1491 ng/L); n = 157; Mann-Whitney U-test, 12.3; P <0.001]. Patients were grouped into diastolic dysfunction [BNP, 195 (223) ng/L], systolic dysfunction [BNP, 290 (394) ng/L], and both systolic and diastolic dysfunction [BNP, 776 (506) ng/L]. In this model, a cutoff value of 50 ng/L BNP increases the diagnostic accuracy in predicting mild HF, avoiding 41 echocardiograms per 100 patients studied, with a net saving of 14% of total costs. CONCLUSIONS: Blood BNP concentrations, in a cost effective targeted screening, can play an important role in diagnosing mild HF and stratifying patients into risk groups of cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Aspromonte et al. (2006) conducted an observational in Mild heart failure (n=252). Brain natriuretic peptide (BNP) testing vs. Patients without heart disease was evaluated on Confirmed heart failure (p=<0.001). Brain natriuretic peptide concentrations were higher in patients with confirmed heart failure than those without heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: